Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study

IF 2.8 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Bingfu Wang, Yulong Song, Yujian Fan, Zhiqiang Zhao
{"title":"Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study","authors":"Bingfu Wang,&nbsp;Yulong Song,&nbsp;Yujian Fan,&nbsp;Zhiqiang Zhao","doi":"10.1155/cdr/1649836","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>Although laxatives are commonly used for constipation in critically ill patients with acute myocardial infarction (AMI), the optimal initial choice is unclear. We are aimed at comparing the clinical outcomes of initiating therapy with stimulant, stool softener, and osmotic laxatives.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study analyzed ICU patients with AMI from the MIMIC-IV database, comparing three initial laxative strategies using propensity score matching (PSM). The primary outcome was 28-day mortality. Secondary outcomes included ICU, in-hospital, and 365-day mortality; cardiogenic shock; malignant arrhythmia; delirium; and bowel sound recovery. Findings were validated with inverse probability of treatment weighting (IPTW) and subgroup analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In the 1:1:1 PSM cohort of 1887 patients, stool softeners were associated with significantly lower mortality versus stimulants: in-hospital (adjusted OR = 0.39, 95% CI 0.22–0.69, p = 0.001), 28-day (aHR = 0.55, 95% CI 0.40–0.76, p &lt; 0.001), and 365-day (aHR = 0.57, 95% CI 0.45–0.72, p &lt; 0.001). Osmotic laxatives correlated with lower in-hospital (aOR = 0.52, 95% CI 0.30–0.89, p = 0.017) and 28-day (aHR = 0.72, 95% CI 0.55–0.95, p = 0.019) mortality, but not 365-day compared with stimulant laxatives. Both agents were linked to lower delirium risk and better bowel sound recovery. IPTW sensitivity analyses showed consistent results.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Among ICU-admitted AMI patients, the initial use of stool softeners or osmotic laxatives was associated with a lower risk of short-term mortality compared with stimulant laxatives. These findings indicate that a more robust and gentle laxative management strategy may have potential clinical value for this high-risk population.</p>\n </section>\n </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069469/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/1649836","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Although laxatives are commonly used for constipation in critically ill patients with acute myocardial infarction (AMI), the optimal initial choice is unclear. We are aimed at comparing the clinical outcomes of initiating therapy with stimulant, stool softener, and osmotic laxatives.

Methods

This retrospective study analyzed ICU patients with AMI from the MIMIC-IV database, comparing three initial laxative strategies using propensity score matching (PSM). The primary outcome was 28-day mortality. Secondary outcomes included ICU, in-hospital, and 365-day mortality; cardiogenic shock; malignant arrhythmia; delirium; and bowel sound recovery. Findings were validated with inverse probability of treatment weighting (IPTW) and subgroup analyses.

Results

In the 1:1:1 PSM cohort of 1887 patients, stool softeners were associated with significantly lower mortality versus stimulants: in-hospital (adjusted OR = 0.39, 95% CI 0.22–0.69, p = 0.001), 28-day (aHR = 0.55, 95% CI 0.40–0.76, p < 0.001), and 365-day (aHR = 0.57, 95% CI 0.45–0.72, p < 0.001). Osmotic laxatives correlated with lower in-hospital (aOR = 0.52, 95% CI 0.30–0.89, p = 0.017) and 28-day (aHR = 0.72, 95% CI 0.55–0.95, p = 0.019) mortality, but not 365-day compared with stimulant laxatives. Both agents were linked to lower delirium risk and better bowel sound recovery. IPTW sensitivity analyses showed consistent results.

Conclusion

Among ICU-admitted AMI patients, the initial use of stool softeners or osmotic laxatives was associated with a lower risk of short-term mortality compared with stimulant laxatives. These findings indicate that a more robust and gentle laxative management strategy may have potential clinical value for this high-risk population.

Abstract Image

急性心肌梗死危重患者初始泻药策略与临床结果的关联:一项回顾性队列研究。
背景:虽然泻药常用于急性心肌梗死(AMI)重症患者的便秘,但最初的最佳选择尚不清楚。我们的目的是比较启动治疗与兴奋剂,大便软化剂和渗透性泻药的临床结果。方法:回顾性分析MIMIC-IV数据库中ICU AMI患者,采用倾向评分匹配(PSM)比较三种初始泻药策略。主要终点为28天死亡率。次要结局包括ICU、住院和365天死亡率;心原性休克;恶性心律失常;精神错乱;肠音恢复。研究结果通过治疗加权逆概率(IPTW)和亚组分析进行验证。结果:在1887例1:1:1 PSM患者队列中,与兴奋剂相比,大便软化剂的死亡率显著降低:住院(调整OR = 0.39, 95% CI 0.22-0.69, p = 0.001)、28天(aHR = 0.55, 95% CI 0.40-0.76, p < 0.001)和365天(aHR = 0.57, 95% CI 0.45-0.72, p < 0.001)。渗透性泻药与较低的住院死亡率(aOR = 0.52, 95% CI 0.30-0.89, p = 0.017)和28天死亡率(aHR = 0.72, 95% CI 0.55-0.95, p = 0.019)相关,但与刺激性泻药相比,365天死亡率不相关。这两种药物都与较低的谵妄风险和更好的肠道声音恢复有关。IPTW敏感性分析结果一致。结论:在icu住院的AMI患者中,与刺激性泻药相比,最初使用大便软化剂或渗透性泻药与较低的短期死亡率相关。这些发现表明,一种更加稳健和温和的泻药管理策略可能对这一高危人群具有潜在的临床价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Therapeutics
Cardiovascular Therapeutics 医学-心血管系统
CiteScore
5.60
自引率
0.00%
发文量
55
审稿时长
6 months
期刊介绍: Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书